Sun Pharmaceutical Industries Ltd has officially denied speculation regarding a potential $10 billion acquisition of US-based Organon, responding to BSE's rumour verification inquiry with a formal clarification that the reports are speculative in nature. The company's response comes after widespread media coverage suggested India's largest drugmaker was evaluating the transformative acquisition that would have marked nearly a decade since Sun Pharma's last major acquisition of Ranbaxy.

Official Company Response to BSE

In a formal communication dated January 19, 2026, Sun Pharma's Company Secretary and Compliance Officer Anoop Deshpande addressed BSE Surveillance regarding news reports about the proposed Organon acquisition. The company categorically stated that the information in media articles is speculative and confirmed no material event or information requires disclosure under Regulation 30 of the Listing Regulations.

Background of Acquisition Speculation

The speculation centered around a potential $10 billion acquisition of Organon, a women's health specialist spun out by MSD (Merck Sharp & Dohme) in 2021. The proposed transaction was reported to include debt and would have positioned Sun Pharma for significant expansion in the US market, particularly in women's health products and biosimilars.

Organon's financial position includes significant inherited debt of $9.50 billion from its 2021 spinoff, with the company actively pursuing divestments to improve its balance sheet. The company's stock experienced volatility, declining from peaks of $17-18 in November 2024 to $8.76, though it surged 28.10% amid acquisition speculation.

Sun Pharma's Current US Market Position

Sun Pharma maintains a strong presence in the US market with its innovative products portfolio reaching $1.21 billion, driven by flagship plaque psoriasis brand Ilumya. The company has established positions in dermatology, onco-dermatology, and ophthalmology through strategic acquisitions including Checkpoint Therapeutics for $416 million and Concert Pharma for $576 million.

Regulatory Compliance and Governance

The company emphasized its commitment to maintaining highest standards of governance and disclosures, stating it will keep stock exchanges informed of any material events as required under Regulation 30 of the Listing Regulations. This response demonstrates Sun Pharma's adherence to regulatory requirements and transparent communication with stakeholders regarding market speculation.

Sun Pharmaceutical has announced the release of Unloxcyt™ (Cosibelimab-IPDL), a new therapeutic option for patients diagnosed with advanced cutaneous squamous cell carcinoma. This launch marks a significant addition to the company's oncology portfolio, providing healthcare professionals with an innovative treatment alternative for this form of skin cancer.

Product Overview

Unloxcyt™ represents Sun Pharmaceutical's latest entry into the specialized oncology market. The treatment is specifically indicated for advanced cutaneous squamous cell carcinoma, a type of skin cancer that requires targeted therapeutic intervention.

Market Impact

The launch of Unloxcyt™ strengthens Sun Pharmaceutical's position in the oncology segment, demonstrating the company's commitment to developing treatments for complex medical conditions. This addition to their therapeutic portfolio provides healthcare providers with another option for managing patients with advanced cutaneous squamous cell carcinoma.

The introduction of this specialized oncology treatment reflects Sun Pharmaceutical's strategic focus on addressing unmet medical needs in cancer care, particularly in the dermatological oncology space.